Agency: European Commission | Branch: H2020 | Program: PCP | Phase: SC1-PM-12-2016 | Award Amount: 4.28M | Year: 2016
Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality. Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals. Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients. Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of 53 billion over 7 years in the four countries. Suppliers can expect a turnover of 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: MSCA-NIGHT-2014 | Award Amount: 248.65K | Year: 2014
The K-TRIO 2 consortium organized in several years Researchers Night in Bulgaria in different cities making people and especially children and youth aware of researchers profession and the contribution of research to economy and society. The public opinion surveys show that the Researchers Night became a popular event in many Bulgarian cities. People enjoy the variety of activities offered and would like to make the Researchers Night a regular Fall rendez-vous in their city with a lot of fun and interaction with researchers. Taking into account the objectives of the Researchers Night initiative of the EC, and the previous experience of the consortium, the project K-TRIO 2 sets as its main goal to enhance public recognition of researchers and innovators and their role in society and to encourage young people in Bulgaria to embark on research career. In the framework of the Europe 2020 strategy, the project focuses on the need for increasing the number of researchers and innovators in Europe and to foster the interest of the society and the youth, in particular, to research and innovation. For achieving the main goal, the following project objectives are defined: - to disclose to the public the hidden sides of life and work of researchers, and show them as professionals and ordinary people; - to highlight the EU emphasis on its researchers, the role of researchers in the Knowledge triangle and for building the Innovation Union; - to involve citizens in debates on the contribution of researchers to European economy and society, as well as in ideas generation and open innovation; - to foster active citizens position on the policy for growing research talents and making research and innovation attractive for young people. The target audience of the project will be on first place young people children, teen-agers and students, and secondly their parents and the public at large. The project K-TRIO 2 will provide various opportunities to citizens in Bulgaria to meet and entertain with researchers.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2011.2.2-02 | Award Amount: 7.84M | Year: 2012
NutriTech will build on the foundations of traditional human nutrition research using cutting-edge analytical technologies and methods to comprehensively evaluate the diet-health relationship and critically assess their usefulness for the future of nutrition research and human well-being. Technologies include genomics, transcriptomics, proteomics, metabolomics, laser scanning cytometry, NMR based lipoprotein profiling and advanced imaging by MRI/MRS. All methods will be applied in an integrated manner to quantify the effect of diet on phenotypic flexibility, based on metabolic flexibility (the capacity for the organism to adapt fuel oxidation to fuel availability). However, NutriTech will move beyond the state-of-the-art by applying these integrated methods to assess the underlying and related cell biological and genetic mechanisms and multiple physiological processes of adaptation when homeostasis is challenged. Methods will in the first instance be evaluated within a human intervention study, and the resulting optimal methods will be validated in a number of existing cohorts against established endpoints. NutriTech will disseminate the harmonised and integrated technologies on a global scale by a large academic network including 6 non-EU partners and by providing an integrated and standardised data storage and evaluation platform. The impact of NutriTech will be multifold and exploitation is crucial as major breakthroughs from our technology and research are expected. This will be achieved by collaboration with a consortium of 8 major food industries and by exploitation of specific technologies by our 6 SME partners. Overall, NutriTech will lay the foundations for successful integration of emerging technologies intro nutrition research.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: HCO-05-2014 | Award Amount: 3.00M | Year: 2014
The Feel4Diabetes project addresses HCO5-2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes. The aim of this project is to develop, implement and evaluate a community-based intervention aiming to create a more supportive social and physical environment to promote lifestyle and behaviour change to prevent type 2 diabetes among families from low and middle income countries and from vulnerable groups in high income countries in Europe. Methods: The PRECEDE-PROCEED Model will provide the theoretical framework for the development, implementation and evaluation of the Feel4Diabetes intervention. The framework has two phases, namely the PRECEDE and PROCEED phase. During the PRECEDE phase, the target population as well as behaviours related to type 2 diabetes and their determinants will be identified. Existing research programs and guidelines for type 2 diabetes prevention, policies, legislation, local infrastructure and human resources will also be recorded. Based on the knowledge gained from this phase, a low-cost and applicable in low-resource settings community-based intervention programme will be developed, with the active engagement of local stakeholders, providing access to the existing infrastructure and human resources wherever feasible. During the PROCEED phase, the intervention will be implemented and its process, impact, outcome, cost-effectiveness and scalability will be evaluated. The results of the intervention will be disseminated, aiming to embed it into policy and practice. Consortium: The Feel4Diabetes multidisciplinary consortium incorporates the necessary expertise on diabetes prevention, behaviours, nutrition, physical activity, policy and health economics. It consists of 10 partners from 7 universities, 1 research institute, 1 advocacy group and a small-medium enterprise, representing European low-middle income, high income and under socioeconomic crisis countries.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: KBBE-2009-2-1-03 | Award Amount: 3.91M | Year: 2010
Objective The ToyBox proposal addresses KBBE-2009-2-1-03 - Behavioural models for prevention of obesity, with a particular focus on children. It will primary aim to influence childrens behaviours and prevent obesity in early childhood. Strategy The proposal will identify key behaviours related to early childhood obesity and their determinants and evaluate behavioural models and educational strategies. Based on the obtained insights at a local level, a multidisciplinary team will develop and implement a school based family involved intervention programme that could be applied on a European scale. Process, impact, outcome and cost-effectiveness evaluation will be conducted to support decision making for European Public Health Policy. Methods The combined use of Precede-Proceed Model and Intervention Mapping will provide the framework for the development, implementation and evaluation of the ToyBox intervention. To achieve this, the project will be subdivided into 10 WPs. This carefully planned stepwise approach will include systematic reviews, secondary analyses of existing data sets, focus group research and school policies overview. Consortium The ToyBox project consortium spans the necessary multidisciplinary variety of experts such as public health experts, epidemiologists, nutritionists, physical activity experts, pedagogists, psychologists, behavioural scientists, nutritionists, paediatricians, early childhood psychologists, health economists, totalling 15 partners, from 10 countries. The consortium, consists of 11 universities, 1 research institute, 2 advocacy groups and an SME representing all regions of Europe. The consortium has ample experience in conducting and coordinating multi-centre international research as well as undertaking dissemination activities to all relevant stakeholders.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-3.2-3 | Award Amount: 2.99M | Year: 2008
In the medium-scale collaborative project with partners inside and outside the EU, scientific institutes with the capacities to conduct sound investigations will cooperate with worldwide active international health service organisations which have information and global links for research on international mobility. General objective is to research on current trends of mobility of health professionals to, from and within the EU. Research will also be conducted in Non-European sending and receiving countries, but the focus lies on the EU: comparative studies in a selected range of representative states will determine the impact of different types of migration on national health systems. An innovative approach will generate more comparable, specified and qualified data gathered by mainly qualitative research and aims for quantities of migration flows as well as detailed qualities like professions, motives, circumstances and the social context, i.e. push and pull factors. Crucial for the approach are key stakeholders which represent the relevant categories in national health systems to collect existing data and statistics, but first of all to generate new, qualitative data. In-depth interviews based on thematic guidelines with representatives of key stakeholders enable a triangulation of data, i.e. the expertise on health professionals mobility and its impact on structures and processes of health systems will qualify the quantitative findings and explore what mobility means for the health system and the persons and organisations involved. The projects policy dimension comprises recommendations on human resource policies in European and third countries for policy and decision makers on the basis of sound empirical research with conceptual frameworks for monitoring systems concerning the mobility of health workers as a key part. Consultation meetings and roundtables with policymakers will be essential in the project.
Chaldakov G.N.,Medical University-Varna
Archives Italiennes de Biologie | Year: 2011
The field of neurotrophins, particularly, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), has witnessed a number of breakthroughs in recent years. There is evidence now that NGF and BDNF mediate multiple biological phenomena, ranging from the Rita Levi-Montalcini's neurotrophic through immunotrophic to epitheliotrophic and nociceptive effects. In 2003 we have enriched the "NGF-ome" with one more expression presented in our concept of NGF metabotrophicity, also that of BDNF. This envisages that these two factors may operate as metabotrophins, that is, involved in the maintenance of cardiometabolic homeostasis (glucose and lipid metabolism as well as energy balance, cardioprotection, and wound healing). Recent results also demonstrated that the circulating and/or tissue levels of NGF and BDNF are altered in cardiometabolic diseases (atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, and type 3 diabetes). Altogether, a hypothesis of metabotrophic deficit due to the reduction of NGF/BDNF availability and/or utilization was raised, and implicated in the pathogenesis of cardiometabolic diseases. This may cultivate a novel pathogenic and therapeutic thinking for these diseases.
Tonchev A.B.,Medical University-Varna
Archives Italiennes de Biologie | Year: 2011
Generation of new neurons persists in the normal adult mammalian brain, with neural stem/progenitor cells residing in at least two brain regions: the subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus (DG). Adult neurogenesis is well documented in the rodent, and has also been demonstrated in vivo in non-human primates and humans. Brain injuries such as ischemia affect neurogenesis in adult rodents as both global and focal ischemic insults enhance the proliferation of progenitor cells residing in SGZ or SVZ. We addressed the issue whether an injury-triggered activation of endogenous neuronal precursors also takes place in the adult primate brain. We found that the ischemic insult increased the number of progenitor cells in monkey SGZ and SVZ, and caused gliogenesis in the ischemia-prone hippocampal CA1 sector. To better understand the mechanisms regulating precursor cell division and differentiation in the primate, we analyzed the expression at protein level of a panel of potential regulatory molecules, including neurotrophic factors and their receptors. We found that a fraction of mitotic progenitors were positive for the neurotrophin receptor TrkB, while immature neurons expressed the neurotrophin receptor TrkA. Astroglia, ependymal cells and blood vessels in SVZ were positive for distinctive sets of ligands/receptors, which we characterized. Thus, a network of neurotrophic signals operating in an autocrine or paracrine manner may regulate neurogenesis in adult primate SVZ. We also analyzed microglial and astroglial proliferation in postischemic hippocampal CA1 sector. We found that proliferating postischemic microglia in adult monkey CA1 sector express the neurotrophin receptor TrkA, while activated astrocytes were labeled for nerve growth factor (NGF), ligand for TrkA, and the tyrosine kinase TrkB, a receptor for brain-derived neurotrophic factor (BDNF). These results implicate NGF and BDNF as regulators of postischemic glial proliferation in adult primate hippocampus.
Ivanova D.G.,Medical University-Varna
Folia medica | Year: 2013
This overview is an attempt to throw a fresh look at the popular free radical theory of aging (referred to also as oxidative stress theory) which holds that the progressive decline in physiological functions is a result of accumulation of diverse deleterious changes caused by reactive oxygen species (ROS). We discuss the role of mitochondria as a major source of ROS in the cell and how these link accumulation of oxidative damage to the age-related changes in physiologic functions. The free radical theory of aging is analysed here from two different views of aging--one (the pessimistic view) that regards aging as the inevitable result of life activity the consequences of which are accumulation of errors in the genome and damage of the biomolecules, and the other (the optimistic view) which considers that it is the changes in mitochondrial pathways of apoptosis with age that cause the functional tissue changes and aging. We also discuss the possibility of delaying the aging process by appropriate diet or drug therapy, which includes also calorie restriction as a mechanism of modifying the generation of free radicals and body metabolism and thus extending lifespan as a result.
Dimitrov D.V.,Medical University-Varna
OMICS A Journal of Integrative Biology | Year: 2011
Demonstrating the importance of the gut microbiota in human health and well-being represents a major transformational task in both medical and nutritional research. Owing to the high-throughput -omics methodologies, the complexity, evolution with age, and individual nature of the gut microflora have been more thoroughly investigated. The balance between this complex community of gut bacteria, food nutrients, and intestinal genomic and physiological milieu is increasingly recognized as a major contributor to human health and disease. This article discusses the "gutome," that is, nutritional systems biology of gut microbiome and host-microbiome interactions. We examine the novel ways in which the study of the human gutome, and nutrigenomics more generally, can have translational and transformational impacts in 21st century practice of biomedicine. We describe the clinical context in which experimental methodologies, as well as data-driven and process-driven approaches are being utilized in nutrigenomics and microbiome research. We underscore the pivotal importance of the gutome as a common platform for sharing data in the emerging field of the integrated metagenomics of gut pathophysiology. This vision needs to be articulated in a manner that recognizes both the omics biotechnology nuances and the ways in which nutrigenomics science can effectively inform population health and public policy, and vice versa. © Copyright 2011, Mary Ann Liebert, Inc.